6
SXTP
vs
S&P 500
S&P 500
Over the past 12 months, SXTP has underperformed S&P 500, delivering a return of -68% compared to the S&P 500's +14% growth.
Stocks Performance
SXTP vs S&P 500
Performance Gap
SXTP vs S&P 500
Performance By Year
SXTP vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
60 Degrees Pharmaceuticals Inc
Glance View
60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. The company is headquartered in Washington, Washington Dc and currently employs 2 full-time employees. The company went IPO on 2023-07-12. The firm is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Its lead product, ARAKODA (tafenoquine), is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. The firm's pipeline under development covers development programs for COVID-19, fungal, tick-borne, and other viral diseases; new products that contain the Arakoda regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. The ARAKODA regimen of tafenoquine is in Phase II study data in patients with mild-moderate COVID-19 disease. The company is also planning a clinical study to assess the utility of ARAKODA as a treatment for human babesiosis. The firm is also developing Celgosivir for the treatment of COVID-19, respiratory syncytial virus (RSV), and dengue.
